B
Björn Konukiewitz
Researcher at Technische Universität München
Publications - 55
Citations - 2236
Björn Konukiewitz is an academic researcher from Technische Universität München. The author has contributed to research in topics: Neuroendocrine tumors & Medicine. The author has an hindex of 22, co-authored 44 publications receiving 1627 citations.
Papers
More filters
Journal ArticleDOI
Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes
Sebastian Mueller,Thomas Engleitner,Thomas Engleitner,Roman Maresch,Roman Maresch,Magdalena Zukowska,Sebastian Lange,Thorsten Kaltenbacher,Thorsten Kaltenbacher,Björn Konukiewitz,Rupert Öllinger,Maximilian Zwiebel,Alex Strong,Hsi-Yu Yen,Hsi-Yu Yen,Ruby Banerjee,Sandra Louzada,Beiyuan Fu,Barbara Seidler,Juliana Götzfried,Kathleen Schuck,Zonera Hassan,Andreas Arbeiter,Nina Schönhuber,Sabine Klein,Christian Veltkamp,Mathias J Friedrich,Lena Rad,Maxim Barenboim,Maxim Barenboim,Christoph Ziegenhain,Julia Hess,Oliver M. Dovey,Stefan Eser,Swati Parekh,Fernando Constantino-Casas,Jorge de la Rosa,Jorge de la Rosa,Marta I. Sierra,Mario F. Fraga,Julia Mayerle,Günter Klöppel,Juan Cadiñanos,Pentao Liu,George S. Vassiliou,Wilko Weichert,Wilko Weichert,Katja Steiger,Wolfgang Enard,Roland M. Schmid,Roland M. Schmid,Fengtang Yang,Kristian Unger,Günter Schneider,Günter Schneider,Ignacio Varela,Allan Bradley,Dieter Saur,Dieter Saur,Roland Rad,Roland Rad +60 more
TL;DR: It is shown that oncogenic dosage-variation has a critical role in PDAC biology and phenotypic diversification, and universal principles of Ras-driven oncogenesis that have potential relevance beyond pancreatic cancer are uncovered.
Journal ArticleDOI
Intraductal neoplasms of the pancreas.
TL;DR: Progress in genetic sequencing of pancreatic neoplasms and the identification of specific genetic mutations also holds promise for the future development of novel gene-based diagnostic tests in intraductal neoplasm of the pancreas that might even be used in preoperative conditions.
Journal ArticleDOI
Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
Björn Konukiewitz,Anna Melissa Schlitter,Moritz Jesinghaus,Dominik Pfister,Katja Steiger,Angela Segler,Abbas Agaimy,Bence Sipos,Giuseppe Zamboni,Wilko Weichert,Irene Esposito,Nicole Pfarr,Günter Klöppel +12 more
TL;DR: This study investigates the expression of somatostatin receptors, p53 and Rb1, and TP53 alterations in pancreatic and extrapancreatic well and poorly differentiated neuroendocrine neoplasms (Ki67-index >20%).
Journal ArticleDOI
Colorectal mixed adenoneuroendocrine carcinomas and neuroendocrine carcinomas are genetically closely related to colorectal adenocarcinomas
Moritz Jesinghaus,Björn Konukiewitz,Gisela Keller,Matthias Kloor,Katja Steiger,Magdalena Reiche,Roland Penzel,Volker Endris,Ruza Arsenic,Gratiana Hermann,Albrecht Stenzinger,Wilko Weichert,Nicole Pfarr,Günter Klöppel +13 more
TL;DR: The identification of BRAF mutations and the frequently present KRAS wild-type status principally render some mixed adenoneuroendocrine carcinomas eligible to targeted treatment strategies used for colorectal adenocarcinomas.
Journal ArticleDOI
R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer.
Ihsan Ekin Demir,Carsten Jäger,A Melissa Schlitter,Björn Konukiewitz,Lynne Stecher,Stephan Schorn,Elke Tieftrunk,Florian Scheufele,Lenika Calavrezos,Rebekka Schirren,Irene Esposito,Wilko Weichert,Helmut Friess,Güralp O. Ceyhan +13 more
TL;DR: Resection margin is not a valid prognostic marker in publications before 2010 due to heterogeneity of cohorts and lack of standardized histopathological examination, and R-status’ prognostic validity may be primarily confined to pancreatic head cancers.